Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2020 | To JAKi or not to JAKi – treating early MF

Ruben Mesa • 31 Aug 2020
Texas MPN Workshop 2020
Myeloproliferative Neoplasms Fedratinib Ruxolitinib

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the issues around early myelofibrosis, and how to treat patients, in particular considering disease burden when selecting a therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ruben Mesa

The MPN Journal: a web-based platform developed by patients for patients 1:05
The MPN Journal: a web-based platform developed by patients for patients
Ruben Mesa • 6 Dec 2025
Impact of thrombocytopenia in JAK inhibitor–naive myelofibrosis treated with ruxolitinib 1:12
Impact of thrombocytopenia in JAK inhibitor–naive myelofibrosis treated with ruxolitinib
Ruben Mesa • 6 Dec 2025
The novel TMPRSS6 antisense inhibitor sapablursen in polycythemia vera: results of IMPRSSION trial 1:24
The novel TMPRSS6 antisense inhibitor sapablursen in polycythemia vera: results of IMPRSSION trial
Ruben Mesa • 8 Dec 2025
Time without transfusion reliance: quantifying transfusion independence in myelofibrosis 3:11
Time without transfusion reliance: quantifying transfusion independence in myelofibrosis
Ruben Mesa • 23 Aug 2025

Related Videos

Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US 2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat 2:12
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat
Prithviraj Bose • 7 Dec 2025
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs 2:40
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
Anand Patel • 25 Nov 2025
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes 4:47
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes
Daniel Wiseman • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals